Travere Therapeutics, Inc. TVTX

SAN DIEGO, September 23, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled "Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders," directed to certain methods of using FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS). Upon issuance, the patent is expected to provide U.S. patent coverage for certain

Travere Therapeutics (NasdaqGM:TVTX) announced a planned CEO and President transition effective December 1, 2026. Dr. Eric Dube will step down from his roles as CEO and President as part of the scheduled leadership change. Bradley L. Campbell has been appointed to succeed Dr. Dube, bringing experience from the rare disease biopharmaceutical sector. This CEO and President transition at Travere Therapeutics is an important development to set alongside the rest of the analysis. We have also...

Travere Therapeutics has delivered a very large share price gain over the past few years, which naturally puts the focus on what investors are paying for its sales today. With the stock now reflecting years of optimism, the immediate question is how well the current valuation lines up with the revenue the business is actually generating. Over the last 3 years the share price has risen by roughly 7x, so anyone looking at Travere Therapeutics now is effectively asking how much of that move is...

SAN DIEGO, September 21, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his health and family. The Company’s Board of Directors has unanimously appointed Bradley L. Campbell, former president and CEO of Amicus Therapeutics, now a wholly owned subsidiary of BioMarin Pharmaceutical Inc., to succeed Dr. Dube as president and chief executive officer a

SAN DIEGO, September 17, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.m. ET.

SAN DIEGO, September 11, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on September 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 16 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 56,220 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan ("2018 Plan") but were granted outside of the 2018 Plan and were grante

Biotech name Travere Therapeutics is not profitable yet but a turnaround may be around the corner as the stock hovers near a buy zone.

Biotech stock TG Therapeutics is building a cup base after a sell-off in early August. It is testing a key moving average.

Travere Therapeutics is Friday's IBD Stock Of The Day. As the Filspari story gets "sweeter," shares are clearing a fresh buy point.

These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months.

Earlier this week, Travere Therapeutics reported Q2 2026 results showing revenue rising to US$169.58 million from US$114.45 million a year earlier, alongside a wider net loss of US$34.8 million versus US$12.76 million. The quarter highlighted record demand for FILSPARI, including strong uptake in IgA nephropathy and an early FSGS launch that outperformed internal expectations despite higher losses and a US$40 million convertible note repurchase charge. Next, we’ll examine how FILSPARI’s...

Travere Therapeutics (TVTX) drew investor attention on 4 August 2026 after reporting second quarter results that combined higher revenue with a wider net loss, driven by performance of its rare kidney disease portfolio. See our latest analysis for Travere Therapeutics. At a share price of $62.45, Travere Therapeutics has a 90 day share price return of 46.6% and a 1 year total shareholder return of 269.31%. This suggests momentum has been building around recent revenue beats and interest in...

Ligand stock landed in a profit-taking zone Thursday on a strong second-quarter report and an earnings guidance hike.